Original Article
Overuse of Acid-Suppression Therapy at an Urban Tertiary Hospital
Abstract
Objectives: Acid-suppressive therapy (AST) is widely used for gastrointestinal prophylaxis in hospitalized patients, particularly to prevent stress-related mucosal bleeding in critically ill individuals. Previous reports suggest gross overutilization and continuation of unnecessary therapy, which have been linked to several adverse effects.Methods: Retrospective chart review at a large tertiary care hospital, evaluating the use of AST for ulcer prophylaxis in accordance with American Society of Health-System Pharmacists’ guidelines and the less commonly studied nonsteroidal anti-inflammatory drug–related ulcer prophylaxis guidelines.
Results: A total of 119 (39.3%) patients who received AST met either American Society of Health-System Pharmacists guidelines or nonsteroidal anti-inflammatory drug–related prophylaxis guidelines. Subjects whose AST was appropriate were older, had a higher Charlson Comorbidity Index ( P < 0.001), and were more often men ( P = 0.005). The rate of discontinuation at discharge was 70.7%; subjects whose prescriptions were not discontinued were older, had a higher Charlson Comorbidity Index, and longer hospital and intensive care unit lengths of stay ( P < 0.001). Family medicine physicians, hospitalists, and surgeons prescribed AST similarly; internal medicine physicians demonstrated higher adherence with guidelines than all others ( P = 0.02). Adherence varied by etiology; cardiology patients were treated with the highest level of appropriateness (53.6%), whereas those admitted for gastrointestinal diagnoses demonstrated the lowest (17.6%, P = 0.03).
Conclusions: Inappropriate prescribing of AST for ulcer prophylaxis remains problematic. There may be differences in prescribing habits of physicians of different specialties. Age and comorbidity scores were associated with inappropriate prescribing and continuation of medication at discharge. Interventions to raise prescribers’ awareness of ulcer risk factors in hospitalized patients, both in the intensive care unit and those who are noncritically ill, are needed.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Guda NM, Noonan M, Kreiner MJ, et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol 2004;99:1233-1237.
2. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561-2568.
3. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951.
4. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1997Y2000. Int J Clin Pharmacol Ther 2003;41:207-212.
5. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005;59:31-34.
6. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J 2010;103:207-211.
7. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122.
8. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-379.
9. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006;101:2200-2205.
10. Hussain S, Stefan M, Visintainer P, et al. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J 2010;103:1103-1110.
11. Bez C, Perrottet N, Zingg T, et al. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract 2013;19:374-378.
12. Lopez-Doriga Bonnardeaux P, Neira Alvarez M, Mansilla Laguia S. Proton bomb inhibitors: a study of the prescription in a functional recovery unit. Rev Esp Geriatr Gerontol 2013;48:269-271.
13. Reid M, Keniston A, Heller JC, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med 2012;7:421-425.
14. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010;5:288-297.
15. Leri F, Ayzenberg M, Voyce SJ, et al. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J 2013;106:270-273.
16. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010;16:122-129.
17. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003;18:847-851.
18. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613-619.
19. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-245.
20. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
21. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121.
22. de Jager CP, Wever PC, Gemen EF, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012;36:941-949.
23. Chan FK. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006;3:563-573.
24. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-738.
25. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296.
26. Issa IA, Soubra O, Nakkash H, et al. Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis. Dig Dis Sci 2012;57:2633-2641.
27. Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci 2009;54:1947-1952.
28. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006;28:189-193.
29. Masica AL, Richter KM, Convery P, et al. Linking joint commission inpatient core measures and national patient safety goals with evidence. Proc Baylor Univ Med Cent 2009;22:103-111.
